The drugmaker beat Q4 estimates as revenue fell 29% to $125.9 mil, topping consensus by about $14 mil. Auxilium Pharmaceuticals' (AUXL) EPS minus items rose 26% to 27 cents a share, beating by 5 cents. The year-ago 4th quarter included a 1-time payment from Pfizer (PFE) on termination of the firms' collaboration. Excluding that payment, sales rose 56%. Its testosterone gel Testim drew the largest share of sales at $59 mil, down 1%. Shares fell 0.3%.